AMLN Amylin Pharmaceuticals, Inc. (MM)

Amylin Pharmaceuticals Withdraws Swiss Regulatory Application for SYMLIN(R) SAN DIEGO, Jan. 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. today announced receipt of correspondence from the Swiss Agency for Therapeutic Products (Swissmedic) indicating that SYMLIN(R) could not be approved for marketing in Switzerland based on data received to date. The Swissmedic indicated that they require additional clinical information to demonstrate the benefits of SYMLIN(R) therapy relative to risks associated with adverse events, including nausea and hypoglycemia. Amylin submitted the original application in August 2001, and in March 2003 submitted a response to the original inquiries from the Swissmedic, which included an interim analysis of a SYMLIN(R) dose-titration study. The Swiss regulatory procedure does not allow for another supplemental submission of data at this stage, therefore, the Company has decided to withdraw its application. "We are currently evaluating our SYMLIN(R) regulatory options in markets in other countries, including resubmission in Switzerland. However, at this time our priority is to gain regulatory approval in the U.S.," said Joann L. Data, MD, PhD, Senior Vice President of Regulatory Affairs and Quality Assurance for Amylin Pharmaceuticals, Inc. "Currently, Amylin's primary focus is to work with the FDA to answer questions posed in the SYMLIN(R) approvable letter received in December 2003." The revision in Amylin's Swiss regulatory strategy for SYMLIN(R) does not affect regulatory strategies being pursued in the U.S. In December 2003, Amylin received a second Approvable Letter from the Food and Drug Administration (FDA) for both type 1 and insulin-using subjects with type 2 diabetes. Final approval is subject to the outcome of further discussions with the FDA. Amylin Pharmaceuticals is committed to improving the lives of people with diabetes and other metabolic disorders through the discovery, development and commercialization of innovative, cost-effective medicines. Further information on Amylin Pharmaceuticals and its pipeline in metabolism is available at http://www.amylin.com/ . This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. The Company's actual results could differ materially from those forward-looking statements discussed in this press release, due to a number of risks and uncertainties, including risks and uncertainties in the ability of the current clinical studies to satisfy the FDA's requirements for SYMLIN(R) approval in the United States, risks and uncertainties in the FDA's review of NDAs generally, risks and uncertainties in FDA requirements for SYMLIN(R) approval, risks and uncertainties that approval by the FDA if any, may be withheld, delayed and/or limited by indications, risks and uncertainties regarding the drug discovery and development process, and uncertainties regarding the Company's ongoing clinical studies of its drug candidates. Additional risks and uncertainties are described more fully in the Company's most recently filed SEC documents, such as its Annual Report on Form 10-K for the fiscal year ended December 31, 2002 under the heading "Risk Factors," its Quarterly Reports on Form 10-Q, and in its recently filed registration statement on Form S-3 (#333-111086). DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Mark G. Foletta, Vice President of Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc., +1-858-552-2200 Web site: http://www.amylin.com/

Copyright